JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

MAP4K

MAP4K inhibitors act on Ste20-related serine/threonine kinases at the top of stress-activated kinase cascades. Mitogen-activated protein kinase kinase kinase kinases (MAP4Ks) include hematopoietic progenitor kinase 1 (HPK1, MAP4K1), germinal center kinase (GCK, MAP4K2) and HPK/GCK-like kinase (HGK, MAP4K4). In 1995 human GCK was shown to activate the stress-activated protein kinase (SAPK) pathway. HPK1 was reported in 1996 to activate the c-Jun N-terminal kinase (JNK) cascade in hematopoietic cells. GNE-495 and PF-6260933 inhibit MAP4K4, while HPK1 is targeted by the inhibitor PF-07265028 and by SS47 TFA, a proteolysis-targeting chimera (PROTAC) degrader. NG25 inhibits MAP4K2 and transforming growth factor β-activated kinase 1 (TAK1), and NCB-0846 targets Traf2- and Nck-interacting kinase (TNIK).

Cat. No.

A65760

CAS No.

2628489-56-3

HPK1 antagonist-1

HPK1 antagonist-1 (I-792) is a selective antagonist of HPK1, a key regulator involved in immune signaling pathways. This compound exhibits significant biological activity by inhibiting HPK1-mediated signaling, making it a valuable tool for investigating its role in cancer progression and immune disorders. Researchers can utilize HPK1 antagonist-1 to explore therapeutic strategies targeting HPK1 in various disease models.

In stock View Details

25 mg

$1,530.00

50 mg

$1,950.00

All 3 sizes

MAP4K

HPK1 antagonist-1